IGKV1-17

Across TCGA pan-cancer cohorts, IGKV1-17 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGKV1-17 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher IGKV1-17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV1-17 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, OV, and LUAD are the cancer types where IGKV1-17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.091	0.830	<.001	36	view →
OV	OS	Median	II,III,IV	0.304	0.691	.030	18	view →
LUAD	OS	Median	III,IV	0.147	0.679	.001	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →
UCEC	DFS	Median	All	1.000	0.630	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IGKV1-17–CESC (OS)

Open the CESC breakdown →